Press Room

Webinar: ASDs by Spray Drying: Process Development & Scale-Up

Start
Wednesday, March 22, 2023 - 16:00
Location: online
Webinar - ASDs Amorphous Solid Dispersions by Spray Drying | Hovione

This is the second session of a three-part webinar series on Amorphous Solid Dispersions by Spray Drying: From Early Formulation to Commercial Lifecycle Management.

 

Watch On-demand. 

Gated content. Registration is required.

 

Learn more about this webinar series here.

 

Featured Hovione experts in this webinar
Clara Sá Couto - Manager, R&D Oral Drug Product - Process Development Team | Hovione
José Luís Santos, Ph.D. Director, Technology Intensification | Hovione
Clara Sá Couto, Ph.D.

Manager, R&D Oral Drug Product,

Process Development Team
José Luís Santos, Ph.D.

Director, Technology Intensification

 

​​​​Clara Sá Couto and José Luís Santos will describe the best practices to transition ASD formulations developed in the laboratory into a reliable industrial process, based upon proven methodologies for process development and scale-up, guaranteeing lean and material sparing approaches. 

The webinar will cover industry standard QbD principles, mathematical models and process development methodologies that benefit from extensive development and manufacturing experience. Existing lab assets will be presented, including a customized spray dryer that can mimic large scale powder properties. Finally, the speakers will guide you through a model-based methodology to establish a design space, to prepare the process for validation and commercial supply.

 

Your Key Learning Objectives: 

  • Understand what to consider for the process development and scale-up of ASD formulations manufactured by spray drying to gain a robust process for validation and commercial supply;
  • ​Discover how to develop an industrially reliable ASD formulation in the lab based on advanced mathematical model to be able to generate optimized process conditions that guarantee seamless scaling-up;
  • Learn how to leverage previous experience, databases, and mathematical models to improve process development and troubleshooting, and to establish an optimized design space to enable flexible manufacturing strategies.

 

Who Should Attend: 

This webinar is suitable for anyone working in formulation and process development of amorphous solid dispersions, procurement, and outsourcing teams or project managers, who are interested in understanding the end-to-end process for developing and scaling-up an ASD by spray drying.

 

 

Watch On-demand. 

Gated content. Registration is required.

 

Do you have a challenging project needing differentiating technologies and an innovative approach?

Get in touch today

 

 

 

Also in the Press Room

See All

Integrated approach simplifies development, reduces risk, and supports scalable manufacturing. Hovione and Industrial Design Consultancy Ltd.’s (IDC) lead single-use nasal dry powder device is now available for commercial partnerships. Hovione and IDC have completed the device design and established initial device manufacturing and supply capability, enabling pharmaceutical partners to leverage existing capsule filling infrastructure. This approach simplifies development, reduces cost and risk, and helps shorten timelines to the clinic and commercialization. “This milestone marks an important step in the evolution of our collaboration with IDC — from device innovation to a fully integrated intranasal drug delivery platform,” said Márcio Temtem, Ph.D., Vice President, Strategic Business Management, Hovione. “As the industry looks for faster, more reliable ways to bring complex therapies to patients, integration becomes critical. By bringing together nasal particle engineering science, formulation manufacturing and filling, and device technologies into a single offering, we enable a more seamless and predictable development journey, accelerating the path to market for intranasal therapies.” The nasal delivery device enables broad and targeted nasal deposition flexibility while delivering maximum usability and reliability. With a patented design and manufacturing process established, the platform is available for partnering with pharmaceutical companies on an exclusive basis as part of Hovione’s integrated offering for inhalation and nasal drug development and manufacturing. Additionally, IDC’s Managing Director, Stephen Knowles Ph.D., said the companies are now “well-advanced” with the development of a multi-use device to support an even wider range of therapies and patient needs. Read the full article at ContractPharma.com    

Press Clipping

Hovione, IDC Launch Intranasal Drug Delivery Platform

May 07, 2026